Anticarcinogen Myricetin is also effective in protecting cells from
carcinogenic mutation. Myricetin reduces the risk of skin tumorigenicity that is caused by
polycyclic aromatic hydrocarbons like
benzo(a)pyrene, a highly carcinogenic compound. Myricetin provided protection against the formation of skin tumors in mice models after tumor initiating and tumor promoter agents were applied to the skin. On a more biochemical level, it was shown that
topical application of myricetin to mice inhibited the binding of benzo(a)pyrenes to DNA and protein native to epidermal skin cells. A current hypothesis for why this occurs can be attributed to myricetin's ability to
chelate iron (Fe) (myricetin ligand forms two or more coordinate bonds to iron). These
in vitro studies cannot be correlated directly to human models and should not be extrapolated. Myricetin also impacts the biochemical efficacy and binding ability of large intracellular biomolecules. Myricetin has been shown to inhibit viral
reverse transcriptase, cellular
DNA polymerase, and cellular
RNA polymerase. Structural analysis of myricetin and other flavonoids with observed antiviral effects indicate that the 3,4' free hydroxyl groups likely are responsible for inhibition.
Antidiabetic Several
in vitro and animal studies have indicated the antidiabetic capabilities of myricetin; however, the evidence in clinical trials is less convincing. The flavonoid has been demonstrated to have a hypoglycemic effect by increasing the ability of adipocytes, as well as cells of the soleus muscle and liver of rats, to uptake glucose. This insulinomimetic effect is hypothesized to be a consequence of myricetin's either direct or indirect interaction with
GLUT4, however, no analysis has produced concrete conclusions detailing exactly from where this effect is derived. In the hepatocytes of rats suffering from diabetes, myricetin has been observed to increase the activity of glycogen synthase 1. In trials done on
Xenopus laevis oocytes, myricetin is thought to regulate the transport of glucose and fructose through the function of glucose transporter 2 (
GLUT2) in sugar absorption. In addition, daily injections of myricetin into rats has been seen to be correlated with increased sensitivity to insulin, indicating the possibility of using a myricetin as treatment or protection against insulin resistance, a frequent cause of diabetes mellitus. In the mouse myoblast cell line known as
C2C12, treatment with myricetin not only increased glucose uptake, but also enhanced
lipogenesis, a result not seen from any of the other bioflavonoids tested. It is also proposed that myricetin may have the ability as a potent flavonoid antioxidant to prevent LDL oxidation, thus slowing the body's local inflammatory response and delaying the appearance of the first fatty streak and onset of atherosclerosis. Although mechanisms relating to myricetin specifically have not been proven, a diet that is rich in fruits and vegetables, and therefore rich in antioxidants, correlates with a decreased risk of cardiovascular disease, including atherosclerosis.
Neuroprotectant It has also been shown that myricetin is effective in protecting neurons against oxidative stressors. Researchers have shown that
PC12 cells treated with hydrogen peroxide (H2O2) as an oxidative stressor experience cell death due to
apoptosis. When treated with myricetin, these oxidatively stressed cells displayed statistically significant increased cell survival. It has been suggested that myricetin not only has oxygen radical scavenging abilities, but also inherent, specific cell-survival capacities. Other molecules known for oxygen radical scavenging (
vitamin E and
boldine) did not successfully protect the cell models from oxidative stress and eventual cell death as effectively as myricetin and other biochemically related molecules.
Anti-platelet aggregation activity Exposure to myricetin caused inhibition of rabbit
platelet aggregation, induced by
adenosine diphosphate,
arachidonic acid,
collagen and
platelet activating factor (PAF). It inhibited specific receptor binding of PAF in rabbit platelets. The compound was found to be active against
thrombin and
neutrophil elastase. In addition, A prostacyclin-stimulated rise in the levels of platelet
adenosine 3',5'-cyclic monophosphate (cAMP) was stimulated by myricetin.
Immunomodulatory activities Myricetin's preclinical
immunomodulatory properties are now becoming increasingly widely known. It was discovered that myricetin may prevent
T-lymphocyte stimulation in a mouse model by binding to anti-CD3 and anti-CD28
monoclonal antibodies immobilised on beads. The inhibitory effect of myricetin on T cells, which was described in this study, was explained as being
mediated via extracellular production. Through the inhibition of NF-B binding activity, these natural compounds were reported to significantly reduce the
lipopolysaccharide (LPS)-induced interleukin (IL)-12 production in mouse main
macrophages as well as the RAW264.7 monocytic cell-line. Myricetin produced
epithelial layer contractile reflexes in separate rat
aortic rings at a concentration of 50 M. This substance induces the synthesis of
cytosolic unbound calcium in cultured
bovine endothelial cells. Myricetin suppressed the release of IL-2 protein from mouse EL-4 T cells that had been stimulated with phorbol 12-myristate 13-acetate (PMA) and
ionomycin in a daily dosage approach. ==References==